Fresenius | FRE - Operating Expenses


Fresenius reported EUR5.25B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Akzo Nobel EUR 2.13B 23M Mar/2026
Alcon AG USD 2.41B 4M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
BASF EUR 14.62B 410M Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Beiersdorf EUR 4.16B 212M Dec/2025
DaVita Healthcare Partners USD -755.5M 3.79B Mar/2026
Demant DKK 9.63B 241M Dec/2025
E.ON EUR 17.71B 2.42B Mar/2026
Essilor EUR 13.09B 1.07B Dec/2025
Fresenius EUR 5.25B 337M Dec/2025
Fresenius Medical Care EUR 4.34B 63M Mar/2026
Getinge SEK 9.99B 2.3B Dec/2024
Givaudan CHF 3B 107M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
GN Store Nord DKK 2.16B 1.94B Mar/2026
GRIFOLS EUR 1.45B 255.28M Mar/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.09B 687M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Philips EUR 3.6B 775M Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
RWE EUR 4.43B 644M Mar/2026
Sanofi EUR 9.31B 1.2B Mar/2026
Smith & Nephew USD 2.52B 84M Dec/2025